Article
Author: Zheng, Jiefang ; Tian, Guanghui ; Hu, Zhengtao ; Zhu, Weiliang ; Zayniddin, Nuriddinov ; Pan, Libiao ; Zheng, Fuqiang ; Li, Pengcheng ; Ji, Jing ; Cheng, Jiaxin ; Aisa, Haji Akber ; He, Yang ; Zhao, Jiangyu ; Hu, Tianwen ; Gong, Xudong ; Abduahadi, Safomuddin ; Shen, Jingshan ; Wang, Guan
Dextromethorphan (DM) is a dual inhibitor of NMDAR and SERT (IC50 (NMDAR): IC50 (SERT) = 31), but lacks therapeutic clinical value for the treatment of depression due to its low exposure in the human body. In this study, a series of d-morphinan derivatives were designed, synthesized and evaluated both in vitro and in vivo to identify dual inhibitors with improved metabolic stability. Structure-activity relationship studies revealed that a methyl group at the morphinan N-17 position is essential for maintaining SERT activity. Amino-morphinan compounds 24 and 27 exhibited moderate yet more balanced inhibitory activity against both NMDAR and SERT (1< IC50(NMDAR): IC50(SERT) < 5). Compared to DM, compound 24 demonstrated favorable metabolic stability and higher plasma exposure. In vivo, 24 showed significant antidepressant-like effects in the forced swim test in mice after acute administration.